Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Capacity of a Camera to Identify Signs of Arteriosclerosis in Retinal Arterioles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02849405
Recruitment Status : Recruiting
First Posted : July 29, 2016
Last Update Posted : March 5, 2018
Sponsor:
Collaborators:
Montreal Heart Institute
Polytechnique Montréal
Information provided by (Responsible Party):
Jean-Claude Tardif, Montreal Heart Institute

Brief Summary:

Arteriosclerosis is a degenerative and dysmetabolic disease of the arterial walls. It is known to be the principal cause of coronary artery disease (CAD). Arteriosclerosis has an impact on the entire vascularization including the microvascularization. The retina is a nervous tissue that is supported by microvascularization. Therefore, systemic diseases that affect the nervous or the cardiovascular system are susceptible to have manifestations in the retina. Retinal signs associated to the risks to develop CAD (qualitative appreciation; diameter and appearance of arterioles) have been suggested. A quantitative approach would strengthen the interpretation of these evaluations.

The Metabolic Hyperspectral Retinal Camera (MHRC) - the experimental instrument - has the capacity to identify and quantify a variety of biomolecules specific to the retina and the optic nerve.

The purpose of this pilot study is to determine if the MHRC has the capacity to detect a specific hyperspectral signature in the retinal arterioles of subjects suffering from arteriosclerosis.


Condition or disease Intervention/treatment Phase
Arteriosclerosis Device: MHRC: Metabolic Hyperspectral Retinal Camera Not Applicable

Detailed Description:

In this pilot study, the main goal is to evaluate the capacity of the Metabolic Hyperspectral Retinal Camera (MHRC) - the experimental instrument - to identify the presence of a specific hyperspectral signature in the retinal arterioles of subjects suffering from arteriosclerosis while this signature should not be present in the retinal arterioles of control subjects considered healthy and without arteriosclerosis risk factors. The study is open, non-controlled and without randomization or placebo.

30 subjects of each group will be enrolled in the study for a total of 60 subjects. Recruitment will take place at the Montreal Heart Institute (Montreal, Quebec, Canada) and will be led by the research team of the Principal Investigator. Specific inclusion/exclusion criteria will differentiate subjects in each group. Once subjects fitting the inclusion/exclusion criteria will be identified, they will be enrolled and asked to sign the informed consent form approved by the Research Ethics and New Technology Development Committee (Montreal Heart Institute).

Following this step, an ophthalmic examination will be performed. During this examination, both eyes will be evaluated in order to detect the presence of eye pathologies (advanced cataracts, venous occlusion, age-related macular degeneration or glaucoma) that could interfere with the analysis of the MHRC optical imaging results. The ophthalmic examination consists first of a slit-lamp evaluation and secondly of an optic coherence tomography (OCT) plus a color image of the fundus (standard instruments commonly used in ophthalmology clinics) following the instillation of eye drops to dilate the pupils. The whole examination should last 45 minutes (it takes 15 to 20 minutes for the pupil to be sufficiently dilated to carry out the examinations). If the ophthalmic examination does not reveal any of the exclusion criteria, in the next minutes, the subject will be asked to undergo the baseline MHRC examination. This baseline imaging session will last a maximum of 15 minutes.

All data according to the light signal spectrum will be analyzed subsequently. Only depersonalized data, identified solely by the subject number, will be used by the investigators.

Risks associated to the subject's participation in this research project have been evaluated. Pupil dilation will be necessary to obtain quality images of the retina using conventional imaging techniques (OCT and fundus) and with the MHRC. The subject's pupils will remain dilated for 4 to 6 hours afterward, which may cause significant glare in areas where light is strong.. The MHRC is a research instrument which images the retina non-invasively and Health Canada authorization has been obtained for its use in the context of this study. The only foreseeable harm connected to its use is discomfort connected to the injection of light into the eye. The power of the monochromatic light source has been calculated to be well below the recommended exposure limits.. Very rigorous verifications were made according to the parameters fixed by the "American National Standard for safe use of laser" (ANSI 136.1) for laser radiation exposure.

Finally, all conflicts of interested are declared in the protocol and the informed consent form. Measures are in place to mitigate them in order to maintain research and data analysis integrity.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Preliminary Evaluation of the Capacity of a Metabolic Hyperspectral Retinal Camera (MHRC) to Identify an Arteriosclerosis Spectral Signature in Retinal Arterioles
Actual Study Start Date : December 21, 2016
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : October 2018

Arm Intervention/treatment
Arteriosclerosis
Hyperspectral camera for arteriosclerosis Diagnostic
Device: MHRC: Metabolic Hyperspectral Retinal Camera
Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.

Healthy controls
Hyperspectral camera for healthy control Diagnostic
Device: MHRC: Metabolic Hyperspectral Retinal Camera
Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.




Primary Outcome Measures :
  1. Spectral intensity measures to visible and near infrared light around retinal arterioles in 30 patients with clearly defined atherosclerosis and 30 controls. [ Time Frame: 1 Year ]
    Data will be aggregated for all arterioles identified in retinal image to produce a single outcome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects suffering from arteriosclerosis:

  1. myocardial infarction
  2. coronary angiography showing at least one coronary stenosis (more than 50%)
  3. and/or coronary angioplasty
  4. and/or coronary bypass.

Healthy control subjects:

  1. absence of a medical history of cardiovascular disease
  2. absence of medical history of cerebrovascular disease
  3. absence of a medical history of peripheral arterial disease

Exclusion Criteria:

Healthy control subjects:

  1. myocardial infarction or angina
  2. known coronary stenosis
  3. coronary angioplasty history or coronary bypass surgery
  4. stroke or transient ischemic attack history
  5. peripheral arterial disease history
  6. active smoking or history smoking in the past 5 years
  7. diabetes mellitus
  8. familial hypercholesterolemia
  9. poorly controlled hypertension (systolic blood pressure ≥150 mm Hg)

All subjects:

  1. medium or high opacity of the lens (which interferes with the MHRC imaging)
  2. bleeding in the vitreous (which interfere with MHRC imaging)
  3. presence of venous occlusion, age-related macular degeneration or glaucoma
  4. pupillary dilation inadequate or contra-indicated
  5. deficient visual fixation
  6. refractive error outside of the range -9 to +9
  7. inability to obtain satisfactory images with the MHRC

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02849405


Contacts
Layout table for location contacts
Contact: David Lapointe, M.Sc. 438-828-1675 dlapointe@optinadx.com
Contact: Jean-Philippe Sylvestre, Eng., Ph.D. 514-966-0325 j-psylvestre@optinadx.com

Locations
Layout table for location information
Canada, Quebec
Montreal Heart Institute Recruiting
Montreal, Quebec, Canada, H1T 1C8
Contact: Gilles Lefebvre    5143763330    gilles.lefebvre@icm-mhi.org   
Principal Investigator: Jean-Claude Tardif, M.D.         
Sponsors and Collaborators
Jean-Claude Tardif
Montreal Heart Institute
Polytechnique Montréal
Investigators
Layout table for investigator information
Principal Investigator: Jean-Claude Tardif, MD Montreal Heart Insitute

Publications:

Layout table for additonal information
Responsible Party: Jean-Claude Tardif, Director, Research Center, Montreal Heart Institute
ClinicalTrials.gov Identifier: NCT02849405     History of Changes
Other Study ID Numbers: ICM-ART-P
First Posted: July 29, 2016    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases